Here, in preclinical models of pancreatic cancer, the authors identify OFD1 as a transcriptional regulator of BRCA1 via the DREAM complex and as a potential therapeutic target in combination with PARP inhibition. This evidence concerns the gene PARP1 and pancreatic neoplasm.